Grounded in rigorous preclinical science.
The founding science originates from the Dr. John and Anne Chong Laboratory for Functional Genomics at the Charles Perkins Centre, University of Sydney, one of Australia's premier translational research centres.
What the lead program has shown.
Restoration, protection and clean delivery.
More new neurons
A roughly 2.5-fold increase in DCX+ newborn neurons in the aged hippocampus, with longer, more arborised neurites, consistent with renewed regenerative capacity.
Neurons protected in disease
Reduced neuronal loss across CA1, CA3 and the dentate gyrus in 5xFAD familial-Alzheimer's mice, an aggressive amyloid model.
Brain-targeted, body-sparing
Biodistribution showed delivery to the brain with no detectable spread to lung, liver, heart, spleen or kidney.
All efficacy and biodistribution figures are from preclinical (cell and mouse) studies. The founding work (Bergamasco, Clark, Loo et al., University of Sydney) is available as a preprint and has not yet been peer reviewed. A PCT patent has been filed on the platform and lead therapeutic application. No L3 Labs product has been tested in or approved for use in humans.
Consistent with the wider literature.
Adult hippocampal neurogenesis declines in Alzheimer's: Moreno-Jiménez et al., Nature Medicine, 2019.
Neurotrophic factors restore memory and synapses in Alzheimer's models: Nagahara et al., Nature Medicine, 2009; neurotrophin biology: Park & Poo, Nature Reviews Neuroscience, 2013.
5xFAD model characterisation: Oakley et al., Journal of Neuroscience, 2006.
Nose-to-brain mRNA-LNP delivery bypassing the blood-brain barrier: Yu et al., ACS Nano, 2026; intranasal CNS delivery pathways: Thorne et al., Neuroscience, 2004.
Diligence-ready preclinical science.
Happy to walk investors and partners through the full preclinical package under confidentiality.
Start a conversation